Protocol CAUSE-05 RHINO (RHINO)
Respiratory Health & Infant Nasal 'Omics (RHINO) (CAUSE-05)
CAUSE-05/RHINO is an observational study designed to learn how babies' nasal cells grow and change during the first months of life. The study will enroll pregnant mothers in their third trimester and their infants upon delivery for a target population of 60 mother-baby pairs. Researchers will conduct up to 6 study visits and collect serial nasal samples through 4 months of age.
研究概览
详细说明
This is an observational, multicenter study designed to assess developmental changes in in vivo and in cultured neonatal nasal epithelial cells. The study will enroll pregnant females in their third trimester of pregnancy as well as their infants upon delivery. Approximately 60 mother-infant pairs will be observed from birth to age 4 months to describe early-life developmental patterns of nasal cell gene expression, including genes related to type-II (T2) inflammation, immune response, and epithelial barrier function.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:James E Gern, MD
- 电话号码:608-263-6201
- 邮箱:gern@medicine.wisc.edu
学习地点
-
-
Illinois
-
Chicago、Illinois、美国、60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
首席研究员:
- Rajesh Kumar, MD
-
接触:
- Sarah Godley
- 电话号码:312-227-6454
- 邮箱:sgodley@luriechildrens.org
-
-
Missouri
-
St Louis、Missouri、美国、63110
- Washington University at St. Louis
-
接触:
- Gina Simpson
- 电话号码:314-362-9139
- 邮箱:simpsong@wustl.edu
-
首席研究员:
- Katherine Rivera-Spoljaric, MD
-
-
Ohio
-
Cincinnati、Ohio、美国、45229
- Cincinnati Children's Hospital Medical Center
-
首席研究员:
- Neeru Hershey, MD
-
接触:
- Molly Brausch-Bradner
- 电话号码:513-803-0028
- 邮箱:molly.brausch-bradner@cchmc.org
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Pregnant maternal participants from the pre-selected recruitment census tracts designated by the CAUSE program, aged 18 years or older, with a gestational age greater than or equal to 28 weeks, in addition to one offspring of each maternal participant.
描述
Inclusion Criteria:
-
Able to understand and provide informed consent
-
Age 18 years or older
-
Currently pregnant, with:
- Gestational age ≥ 28 weeks as confirmed by participant self-report
- Intent to deliver at a participating clinical site labor and delivery (L&D) center
-
Agrees to enroll infant into the study at birth
-
In the case of multiple gestation, agrees to enroll only one infant who will be randomly selected
-
Have a primary place of residence in one of the pre-selected recruitment census tracts as outlined in the Protocol CAUSE-05 (RHINO) Manual of Procedures (MOP) a. Participants who do not live in the pre-selected census tracts but live within the Office of Management and Budget (OMB) defined Metropolitan Statistical Area and have publicly funded health insurance will qualify for inclusion.
Exclusion Criteria:
- Inability or unwillingness to give written informed consent or comply with study protocol
- Insufficient proficiency in English or Spanish to provide informed consent and complete study procedures
- Obstetric complications present and/or anticipated that could, in the opinion of the investigator, impact the study objectives
- Pregnancy conceived via donor oocyte (egg donation)
- Known plans to move outside the pre-selected recruitment census tracts before the infant reaches 4 months of age
- Intent to transfer infant custody (e.g., via adoption or foster placement) within 4 months of birth
- Past or current medical problems that are not listed above, which, in the opinion of the investigator, may pose additional risks related to participation in the study, may interfere with the participant's ability to comply with the protocol, or may impact the interpretation of data obtained from the study.
Infants who meet any of the following criteria at the Birth Visit are not eligible for further study participation:
- Delivery before 36 weeks gestation
- Diagnosed at birth with any medical condition which, in the opinion of the investigator, may pose additional risks related to participation in the study, may interfere with the family's ability to comply with the protocol, or may impact the interpretation of data obtained from the study.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
Pregnant females 18 years and older and their infants upon delivery
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Gene expression of nasal swab RNA samples
大体时间:4 months
|
Gene expression will be measured by whole transcriptome RNA sequencing |
4 months
|
合作者和调查者
调查人员
- 学习椅:James E Gern, MD、University of Wisconsin, Madison
- 学习椅:Jo L Wilson, MD、University of Wisconsin, Madison
- 研究主任:Daniel Jackson, MD、University of Wisconsin, Madison
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- DAIT CAUSE-05
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Immunonology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
IPD 共享时间框架
On average, within 24 months after database lock for the trial.
IPD 共享访问标准
Open access
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.